CB2 Insights Partners With Vireo Health To Help Advance Medical Cannabis Clinical Trial

excerpt, News, stream

CB2 Insights (CSE: CBII) (OTC: CBIIF) said Tuesday it has partnered with Vireo Health International Inc. (CNSX: VREO) (OTC: VREOF) to improve the proof of safety and efficacy for cannabinoid therapy.

CB2 is supposed to control the protocol development and Investigational New Drug Application straight with the FDA. Upon the favorable completion, Vireo should become one of the industry leaders in cannabis-based topical medication for alleviating pain, the company said.

Vireo will license the company’s Sail technology platform for complete data collection and organization.

Don’t miss out on the top cannabis stories of the …

Full story available on Benzinga.com

Follow MrTopStep in our Social Space:

Tradechat (2068 Posts)


Leave a Reply